According to EU-Startups, French preventive healthcare startup Lucis has raised a €7.2 million Seed round. The funding was led by General Catalyst, with participation from Y Combinator, Kima Ventures, Motier Ventures, Circle.Co, and North South Ventures. Founded in 2025 in Paris by Maxime Berthelot, Baptiste Debever, and Max Gueroi, the company offers AI-supported analysis of over 180 biomarkers from lab tests. CEO Maxime Berthelot stated the goal is to democratize disease prevention by connecting lab analyses, medical expertise, and a user-friendly platform. The cash will boost European expansion, broaden its network of partner labs and physicians, and scale its platform. Lucis has already conducted over 500,000 clinical tests in France, the UK, Ireland, and Portugal.
The Prevention Play
Here’s the thing: everyone’s talking about “health optimization” and longevity these days, but actually getting clear, actionable data is still a hassle. Lucis is jumping into that gap. They’re not trying to be a doctor—they hammer that point home—but a super-powered, data-driven starting point. You get your blood drawn at a certified lab, their AI and medical team crunch 180+ biomarkers, and they give you a dashboard and a plan focused on nutrition, supplements, activity, sleep, and mental health. It’s basically a comprehensive, tech-forward version of an executive physical, but aimed at a broader audience. The timing seems right, with more people wanting to be proactive rather than just reactive with their health.
Funding And Foothold
Pulling in General Catalyst and Y Combinator is a serious vote of confidence. That’s Silicon Valley’s A-list saying the European preventive health market is ripe. The €7.2 million is a hefty seed round, which tells you they need capital for physical expansion—signing up labs and doctors across borders isn’t cheap or easy. They already have a footprint with 500,000 tests in four countries, which is a solid foundation to scale from. But now the real work begins. Can they maintain that “clear, user-friendly” experience as they grow? And will their strict “we are not a replacement” positioning hold up if users start relying on the platform for answers? It’s a tricky line to walk.
business-of-not-being-medical”>The Business Of Not Being Medical
Their entire model hinges on that careful positioning: a preventive tool, not a medical platform. It’s smart from a regulatory standpoint, but it also defines their business model. They’re selling information and guidance, not diagnoses or cures. The beneficiary is ostensibly the individual user getting early insights. But the real commercial scalability might come from partnering with employers or insurers down the line, offering this as a wellness benefit. With this funding, broadening the physician and lab network is key. If they can make the process seamless and the results genuinely insightful, they could carve out a big niche. But the space is getting crowded. They’ll need that Y Combinator and General Catalyst savvy to out-execute the competition. You can check out their platform at Lucis.life.
